image: He shares insights on AI-driven sustainability efforts under the title “From drug discovery and productive longevity to sustainability” at 3:05 PM on September 24.
Credit: Insilico Medicine
Held annually, NY Climate Week is a pivotal event in the global climate change calendar. Bringing together notable leaders, celebrities, climate professionals, and innovators from around the world, the event serves as a critical platform for discussing and advancing climate action. This year’s theme, "It’s Time," underscores the urgency for immediate and ambitious efforts to tackle climate change, and the process could be accelerated with Generative AI and other cutting-edge technologies.
Insilico Medicine (“insilico”), a leading company in AI-driven drug discovery, is proud to announce that our Founder and CEO, Alex Zhavoronkov, PhD, will be presenting at the AWS Climate Tech & AI Forum during NY Climate Week, where he shares insights on AI-driven sustainability efforts under the title “From drug discovery and productive longevity to sustainability” at 3:05 PM on September 24. The forum provided a unique platform to address the urgent need for innovative climate solutions.
The AWS Climate Tech & AI Forum focuses on topics including foundational models, sustainable material discovery, virtual agents and synthetic data, discussing the application generative AI and machine learning in product development, cost reduction, emission control and creating climate solutions that were previously unimaginable.
Even before the announcement of the Generative AI for Environmental Sustainability Consortium on the Insilico Medicine Generative Artificial Intelligence Action (IMGAIA) webinar in July 2024, Insilico has been exploring AI-powered sustainable development. Today, Insilico is actively venturing into agrochemistry, hydrogen storage, CO2 capture and other applications with the support of partners including Syngenta and Saudi Aramco.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry and clinical development. Powered by Pharma.AI, Insilico has nominated 19 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND approval for 9 molecules.
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001_055, the company’s lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001_055 showed dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com